PRECISION BIOSCIENCES INC
For the period ended Mar 26, 2025. Filed Mar 26, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Mar 26, 2025 · Filed Mar 26, 2025
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · ARCUS Platform
ARCUS Platform
At the ESGCT 31st Annual Congress in October 2024, Precision presented preclinical data highlighting ARCUS’s capability for high-efficiency gene editing to achieve a range of gene editing outcomes, including specific base correction, insertions, and the replacement of large segments of DNA within the genome via homology-directed repair (HDR). The presentation also discussed how the ARCUS approach may provide broader therapeutic applicability and address significantly more diseases through gene insertion and repair than other gene editing modalities which primarily target gene deletion or knock out.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.